Pressmeddelanden från Zelluna

Bevaka pressreleaser

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Zelluna ASA – Mandatory notification of trade 26 mar 15:28

Zelluna to host Capital Markets Update 2026 26 mar 08:57

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 25 mar 07:00

Zelluna ASA [ZLNA]: Annual Report 2025 09 mar 08:00

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering 20 feb 14:30

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial 12 feb 07:00

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission 11 feb 08:00

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial 05 feb 13:30

Zelluna ASA - Grant of Share Options 05 feb 09:30

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation 03 feb 08:00

Zelluna promotes Emilie Gauthy to Chief Technology Officer 15 jan 12:23

Zelluna ASA: Approval and publication of prospectus 17 dec 2025 17:26

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours 16 dec 2025 12:37

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours 12 dec 2025 13:02

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial 09 dec 2025 09:36

Zelluna ASA: Cancellation of subsequent repair offering 08 dec 2025 18:36

Zelluna ASA - Mandatory notification of trade 08 dec 2025 13:52

Zelluna ASA: New share capital registered 28 nov 2025 07:50

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer 27 nov 2025 08:35

Zelluna ASA: Disclosure of large shareholding 25 nov 2025 11:32

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025 17 nov 2025 10:33

Zelluna ASA: New share capital registered 04 nov 2025 13:04

Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 04 nov 2025 09:11

Zelluna ASA: Disclosure of large shareholding 04 nov 2025 07:29

Zelluna ASA: Disclosure of large shareholding 04 nov 2025 07:00

Zelluna ASA – Ex. date 04 nov 2025 00:58

Zelluna ASA – Key information relating to subsequent offering 04 nov 2025 00:35

Zelluna ASA - Mandatory notification of trade 03 nov 2025 23:52

Zelluna ASA - Successful private placement and retail offering 03 nov 2025 16:47

Zelluna ASA – Contemplates private placement 03 nov 2025 16:39

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update 09 okt 2025 07:58

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK 10 sep 2025 08:00

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025 20 aug 2025 07:00

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update 14 aug 2025 12:00

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation 03 jul 2025 12:07

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program 25 jun 2025 16:19

Disclosure of share transfer from Inven2 AS 27 maj 2025 13:52

Disclosure of Shareholding – Gjelsten Holding AS 27 maj 2025 13:38

ZLNA – New registered share capital 24 maj 2025 08:38

ZLNA – Issuance of shares through set-off of option exercise fee 08 maj 2025 07:00

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update 30 apr 2025 08:00

Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation 29 apr 2025 14:50

Zelluna ASA – Annual General Meeting held on April 29, 2025 22 apr 2025 07:47

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours 04 apr 2025 15:21

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider 04 apr 2025 07:00

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025 02 apr 2025 07:00

Zelluna ASA [ZLNA]: Annual Report 2024 01 apr 2025 08:00

Zelluna ASA [ZLNA]: Ex reverse share split today 31 mar 2025 17:16

Zelluna ASA [ZLNA]: Registration of reverse share split 27 mar 2025 15:28

Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN 27 mar 2025 10:21

Zelluna ASA [ZLNA]: Share capital increase registered 26 mar 2025 13:55

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider 26 mar 2025 13:22

Zelluna ASA [ZLNA]: Share capital increase resolution 03 mar 2025 16:46

Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement 28 feb 2025 14:45

Ultimovacs ASA: Approval and publication of prospectus 13 feb 2025 17:30

Ultimovacs ASA: Cancellation of subsequent repair offering 31 jan 2025 07:00

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update 27 jan 2025 08:48

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation 09 jan 2025 12:00

Ultimovacs ASA: Notification of major holdings 09 jan 2025 10:00

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025 08 jan 2025 12:00

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting 06 jan 2025 12:00

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting 05 jan 2025 20:28

Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025 19 dec 2024 09:37

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION 19 dec 2024 07:00

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 18 dec 2024 08:00

ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY 17 dec 2024 19:39

Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA 17 dec 2024 19:25

Ultimovacs ASA – Mandatory notification of trade 17 dec 2024 17:53

ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT 06 nov 2024 07:00

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update 31 okt 2024 07:00

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation 25 okt 2024 17:00

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv 11 sep 2024 17:00

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer 09 sep 2024 00:10

Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 21 aug 2024 07:00

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 15 aug 2024 07:00

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation 07 aug 2024 13:59

Ultimovacs Announces Notice of Resignation from Deputy Board Member 05 aug 2024 19:12

Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer 01 aug 2024 17:20

Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 24 jun 2024 21:00

Ultimovacs ASA announces revised terms of the employee share option program 11 jun 2024 07:00

Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab 01 jun 2024 14:15

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 07 maj 2024 07:00

Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update 30 apr 2024 07:00

Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation 24 apr 2024 16:15

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 18 apr 2024 14:42

Ultimovacs ASA – Annual General Meeting held on April 18, 2024 16 apr 2024 22:10

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program 15 apr 2024 07:00

Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting 09 apr 2024 20:00

Ultimovacs – Invitation to Business Update on April 17, 2024 04 apr 2024 07:00

Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 25 mar 2024 07:00

Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 22 mar 2024 13:27

Ultimovacs ASA: Mandatory notification of trade by primary insider 21 mar 2024 07:00

Ultimovacs ASA: Annual Report 2023 09 mar 2024 11:00

Ultimovacs ASA: Mandatory notification of trades by primary insider 08 mar 2024 23:00

Ultimovacs ASA: Mandatory notification of trades by primary insider 07 mar 2024 23:00

Ultimovacs ASA: Mandatory notification of trade by primary insiders 07 mar 2024 07:00

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma 02 mar 2024 18:41

Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer 22 feb 2024 08:20

BioStock: Ultimovacs receives Orphan Drug Designation from EMA 22 feb 2024 08:20

BioStock: Ultimovacs erhåller särläkemedelsstatus från EMA